Exelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has determined the company’s supplemental New ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Exelixis (EXEL) PT Raised to $35 at SunTrust Robinson HumphreyOctober 16, 2017 11:16 AM Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell CarcinomaOctober 16, 2017 6:59 AM